Ocular Surface Disease: Pathophysiology, Evaluation, Management with Topical Agents, and Neuromodulation

Complimentary

Live Virtual Webinar:
Saturday, March 8, 2025: 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT

Categories: , , , , , , , , , ,
Close-up of a human eye with a futuristic, glowing digital interface.

Take Me to the Event Registration

Program Description

Click to Go to the Event Registration

This program will provide up-to-date, evidence-based information on pathophysiology, evaluation, topical agents, and neuromodulation in managing OSD. The activity will focus on:

  • Pathophysiology – Normal ocular surface physiology, including the role of the lacrimal functional unit in stimulating the lacrimal gland, meibomian glands, and goblet cells.
  • Risk factors for OSD – Contact lens wear, ocular surgery, extensive digital device use, and eye makeup.
  • Evaluation – Symptom questionnaires, tear breakup time, tear volume assessment, and ocular surface staining
  • Management of OSD with Artificial Tears – Artificial tear formulations and benefits in managing different dry eye sub-types
    • Active and inactive ingredients, including the role of inactive ingredients in optimizing delivery and retention time.
    • Preserved vs preservative-free (unit dose vs multi-dose dispensing methods)
    • Lipid-enhanced vs. non-lipid-enhanced.
    • The efficacy and safety profile of short-term and chronic treatment options for inflammatory dry eye.
  • Neuromodulation in OSD – Neural network that monitors the ocular surface environment and regulates tear secretion.
    • Afferent sensory fibers in the nasal mucosa and ocular surface (nicotinic muscarinic receptors and TRP receptors).
    • Efferent parasympathetic pathways and targets (lacrimal gland, meibomian glands, and goblet cells.
    • Neurotrophic Keratopathy (NK) – Clinically, stage 1 NK is similar to moderate-to-severe dry eye disease (DED) or many other epitheliopathies
    • Cenegermin is a recombinant human nerve growth factor (rh-NGF) that supports corneal reinnervation.

Agenda

• Overview of the pathophysiology, risk factor, and evaluation of ocular surface disease (OSD) – Sarah B. Sunshine, MD

• Discuss the data on artificial tear formulations and neuromodulation in managing OSD – TBD

Intended Audience

Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease

Commercial Supporter

Supported by an unrestricted educational grant from Dompé US Inc.

Learning Objectives

  • Summarize the pathophysiology, risk factor, and evaluation of ocular surface disease
  • Interpret data on artificial tear formulations and neuromodulation in managing ocular surface disease

Accredited Providers

Amedco and MedNet have collaborated to design and execute this activity.

      

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and MedNet. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Amedco Joint Accreditation #4008163.

Physicians (ACCME) Credit Designation

Amedco LLC designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Optometrists Credit

This activity, COPE Activity Number 130237, is accredited by COPE for continuing education for optometrists.

MedNet designates this activity for a maximum of 1.25 COPE credits.

Additional Credit Information

Physician Assistants
PAs may claim a maximum of 1.25 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 CreditTM from organizations accredited by ACCME or a recognized state medical society.

Nurse Practitioners
The American Association of Nurse Practitioners (AANP) recognizes the Accreditation Council for Continuing Medical Education (ACCME) and the American Nurses Credentialing Center (ANCC) as approved accreditors and allow reciprocity for AANPCP continuing education credit. 1.25 hours.

Disclosures of Relationships with Ineligible Companies Policy

In accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education, all faculty, planning committee members, and other individuals, who are in a position to control content, are required to disclose all relationships with ineligible companies* (commercial interests) within the last 24 months. All educational materials are reviewed for fair balance, scientific objectivity, and levels of evidence. The ACCME requires us to disqualify from involvement in the planning and implementation of accredited continuing education any individuals (1) who refuse to provide this information or (2) whose conflicts of interests cannot be mitigated.

Planners’ and Managers’ Disclosures

All relevant relationships have been reviewed and mitigated.

Off-Label Disclosure Statement

Faculty members are required to inform the audience when they are discussing off-label, unapproved uses of devices and drugs. Physicians should consult full prescribing information before using any product mentioned during this educational activity.

Faculty

Sarah B. Sunshine, MD
Assistant Professor
Ophthalmology, University of Maryland and Greenebaum Comprehensive Cancer
Baltimore, MD

Instructions/Technical Requirements

Hardware: An internet-enabled computer, smartphone, tablet, or other mobile device with audio and internet capabilities.

Software: Installation of software like Zoom may be necessary.

    Cost

    There are no fees for participating and receiving CME and COPE credit for this activity.

    Contact

    Brian Waggoner
    Program Manager
    MedNet
    brianw@mmhus.net

    EVENT Summary

    Dates

    Saturday, March 8, 2025, 10:00 AM ET, 9:00 AM CT, 8:00 AM MT, and 7:00 AM PT

    Location

    Virtual

    Target Audience

    Ophthalmologists, optometrists, and advanced practice providers (physician assistants and nurse practitioners) who manage patients with ocular surface disease

    Format

    Zoom Webinar

    Credits

    1.25 / AMA PRA Category 1 Credit(s)TM
    1.25 / COPE CE Credits

    Cost

    Complimentary

    Related products